Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. [electronic resource]
Producer: 20110812Description: 2357-63 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Benzimidazoles -- adverse effects
- Biliary Tract Neoplasms -- drug therapy
- Extracellular Signal-Regulated MAP Kinases -- metabolism
- Female
- Humans
- MAP Kinase Kinase 1 -- antagonists & inhibitors
- MAP Kinase Kinase 2 -- antagonists & inhibitors
- Male
- Middle Aged
- Mutation
- Neoplasm Metastasis -- drug therapy
- Phosphorylation
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins B-raf -- genetics
- Proto-Oncogene Proteins c-akt -- metabolism
- Proto-Oncogene Proteins p21(ras)
- ras Proteins -- genetics
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.